Established field-portable drug detection technologies such as Raman and FTIR are designed to work primarily on formulations where compounds of interest are present at a high purity. These instruments perform poorly on mixtures containing a low concentration of active compound, meaning detection of drugs including SCs directly from eliquid is not feasible. Lab-based testing approaches (i.e., GC-MS) are used as the gold standard for assessing drug content of suspicious e-cigarettes, but are limited by turnaround time, primarily restricting use to evidentiary analysis. We were motivated by the current lack of point-ofcare testing technology to develop a device that can rapidly report on drug content of sealed e-cigarettes and e-liquids liquids, to be deployed to inform urgent care.